Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 17/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.46 |
| ▸ | PIK3R2 | O00459 | 6/20 | 0.46 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2510524 | 0.88 | PIK3CG (0.47) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA | |
| SCHEMBL2506846 | 0.87 | PIK3CD (0.48) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA | |
| SCHEMBL2506848 | 0.87 | PIK3CD (0.48) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA | |
| SCHEMBL2503185 | 0.86 | PIK3CD (0.62) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA | |
| SCHEMBL2505862 | 0.85 | PIK3CD (0.49) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA | |
| SCHEMBL2505055 | 0.82 | PIK3CD (0.43) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA | |
| SCHEMBL12223743 | 0.80 | PIK3CG (0.51) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA | |
| SCHEMBL2510704 | 0.78 | PIK3CD (0.60) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA | |
| SCHEMBL2507261 | 0.77 | PIK3CD (0.59) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA | |
| SCHEMBL2505704 | 0.77 | PIK3CD (0.64) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552908-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2013-02-06 | — | — | EP | claimed |
| WO-2011123751-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-10-06 | — | — | WO | claimed |
| US-8575183-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575183-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575183-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2552908-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011123751-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20110245257-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245257-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245257-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CD 16/4885PIK3CG 54/4885PIK3R2 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.